Clinical Trials Logo

Clinical Trial Summary

This study is a phase I clinical study of the safety, tolerability, and pharmacokinetics of BAT4406F injection in patients with neuromyelitis optica spectrum disorders.


Clinical Trial Description

This is a Phase 1, open-label, dose-escalation study in NMOSD patients in which subjects will receive BAT4406F injection via intravenous infusion. A 3 + 3 design will be utilized to define a maximum tolerated dose (MTD). The overall objective is to assess the safety, tolerability, and pharmacokinetics of BAT4406F injection in NMOSD patients. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04146285
Study type Interventional
Source Bio-Thera Solutions
Contact Qiang Wei
Phone 17768126490
Email qwei@bio-thera.com
Status Recruiting
Phase Phase 1
Start date September 1, 2020
Completion date June 1, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT02836327 - Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders N/A
Not yet recruiting NCT06068829 - Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disorders
Recruiting NCT05204459 - MS-ResearchBiomarkerS
Completed NCT03350633 - Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders Phase 2/Phase 3
Completed NCT04388072 - An Diagnostic Cohort on AQP4-Immunoglobulin G Detection Kit
Completed NCT05871658 - Efficacy of Electroacupuncture in NMOSD Patients With Pain: Study Protocol N/A
Recruiting NCT02021825 - Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Phase 4
Recruiting NCT06249438 - A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy Phase 1
Not yet recruiting NCT06413654 - A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) Phase 2/Phase 3
Recruiting NCT03330418 - A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders Phase 3
Enrolling by invitation NCT04101058 - Treatment Response Among Chinese Neuromyelitis Optica Spectrum Disorders
Enrolling by invitation NCT02809079 - Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients Phase 4
Recruiting NCT02889965 - The French Multiple Sclerosis Registry N/A
Completed NCT02850705 - The French Cohort and Biobank of Devic's Neuromyelitis Optica and Related Neurological Disorders (NMOSD) (NOMADMUS)
Completed NCT04670770 - An Open Label Study of the Effects of SHR1459 in NMOSDs Patients Phase 2
Not yet recruiting NCT06212245 - A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders Phase 4
Completed NCT03062579 - A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD Phase 1/Phase 2
Recruiting NCT05730699 - Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE) Phase 3